000			05027nam a2200421 i 4500
999			_c361212 _d361212
001			361212
003			ES-MaUEC
005			20230102121331.0
006			a||||fo|||| 00| 0
007			cr nn nnnaamaa
008			210928s2021 sz | o |||| 0|eng d
020			_a9783030783150
024	7		_a10.1007/978-3-030-78315-0 _2doi
040			_aES-MaUEC _bspa _cES-MaUEC _dES-MaUEC
050		4	_aQH581.2 _b2021 EB
245	1	0	_aNuclear Receptors : _bThe Art and Science of Modulator Design and Discovery _cedited by Mostafa Z. Badr
250			_aFirst edition 2021
264		1	_aCham _bSpringer International Publishing _c2021
300			_a1 recurso en línea (XI, 679 páginas) _b209 ilustraciones, 127 ilustraciones a color
336			_2rdacontent _aTexto _btxt
337			_2rdamedia _aelectrónico _bc
338			_2rdacarrier _arecurso electrónico _bcr
347			_aArchivo de texto _bPDF
490	0		_aBiomedical and Life Sciences (SpringerNature-11642)
490	0		_aBiomedical and Life Sciences (R0) (SpringerNature-43708)
505	0		_a1. Molecular Pharmacology of the Youngest Member of the Nuclear Receptor Family: The Mineralocorticoid Receptor -- 2. A Simple Method for Visual Assessment and Quantification of Altered Subcellular Localization of Nuclear Receptors -- 3. Multifaceted Effects of Ligand on Nuclear Receptor Mobility -- 4. Chemical Considerations in Discovery of Receptor Modulators -- 5. Structure-Based Design of Estrogen-Related Receptors Modulators -- 6. PPARα and δ ligand design - Honing the traditional empirical method with a more holistic overview -- 7. Pregnane X Receptor: understanding its function and activity at the molecular level -- 8. Ligand Design for the Vitamin D Receptor -- 9. What Makes a Good Antagonist: Lessons Learned from the Estrogen and Aryl Hydrocarbon Receptors -- 10. Design of Novel PPAR agonist for Neurodegenerative Disease -- 11. Functional bioassays lithograph ligand reflections in the PPARalpha sphere -- 12. Computational applications on Food Contact Chemicals as Nuclear Receptors binders -- 13. Alternation of Nuclear Hormone Receptor Signaling by Antiviral Drugs -- 14. Retinoic acid-related orphan receptor (ROR) inverse agonists: potential therapeutic strategies for multiple inflammatory diseases -- 15. Therapeutic Strategies to Target Activating Estrogen Receptor a Mutation -- 16. Androgen Receptors in the Pathology of Disease -- 17. Bilirubin: A Ligand of the PPARα Nuclear Receptor -- 18. Nuclear Receptor Ligands in Flavivirus Infection Control -- 19. Use of Nanotechnology to Improve 15d-PGJ2 Immunomodulatory Activities -- 20.Ligand-independent Activation of PPARs -- 21. PPAR Modulation Through Posttranslational Modification Control -- 22. Developing Inhibitors to the Amino-Terminus Domains of Steroid Hormone Receptors -- 23. Redirecting the cellular waste disposal machinery to target transcription.
520	3		_aNuclear receptors are ligand activated transcription factors that control numerous biological functions. Consequently, altering activity of these receptors is proposed, and indeed documented, to affect many physiological and pathological conditions in experimental animals and humans. Thus, nuclear receptors have become a major target in the effort to treat numerous diseases. This book will shed light on and emphasize intricate processes involved in designing as well as discovering physiological and pharmacological modulators of these important proteins. World-renowned scientists will share with the reader their professional expertise and extensive experience acquired through decades working with nuclear receptors. Chapters address the various means and consequences of modulating nuclear receptor activity will be presented and discussed. These modulators cover a wide span of moieties ranging from synthetic chemicals to natural products. In addition, the classification of these chemicals ranges from pan agonists to selective agonists and inverse agonists to antagonists. They also include proteolytic means to obliterate the receptor in the event that modulating its activity through canonical pharmacological agents becomes less effective and/or less desirable due to anticipated or experienced toxicities. Modulation of receptor activity may also take place in the absence of a ligand or through manipulating the structure of the receptor itself by controlling posttranslational events.
988			_aSpringer_BiomedLife_2021
650		7	_2embne _aCitología _9139477
650		7	_2embne _aMetabolismo _9138638
700	1		_aBadr, Mostafa Z. _eeditor literario _4edt _4http://id.loc.gov/vocabulary/relators/edt
776	0	8	_iPrinted edition: _z9783030783143
776	0	8	_iPrinted edition: _z9783030783167
776	0	8	_iPrinted edition: _z9783030784386
856	4	0	_uhttps://go.openathens.net/redirector/universidadeuropea.es?url=https://doi.org/10.1007/978-3-030-78315-0 _zAcceso a este recurso digital (usuarios Universidad Europea de Madrid)
942			_2lcc _cLE
998			_b01/2022 _dz _eb _zSI